Trial Information

Summary: Evaluate a novel compound in subjects with Occluded Central Venous Access Devices.

Objective is to evaluate the safety of study drug by monitoring of adverse events and major bleeding events for up to 120 minutes following its instillation of final dose.

Several Study Inclusion Criteria Include:

• Unable to withdraw 3 mL of blood from a central venous access device.
• Hemodynamically stable

Several Study Exclusion Criteria Include:

• Inability to infuse at least 2 mL of saline through catheter
• In the opinion of investigator, subject is at "high risk" for bleeding events or embolic complications.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: February 25, 2008 at 2:32:24 PM